abstract |
The present invention relates to the treatment of insulin resistance disorders. In particular, the present invention relates to the administration of IL-17 antagonists such as IL-17A and / or IL-17F, eg, anti-IL-17A and / or IL-17F and / or IL-17Rc antibodies, or antibody fragments. By the treatment of insulin resistance disorders. |